The Essential Thrombocythemia drugs in development market research report provides comprehensive information on the therapeutics under development for Essential Thrombocythemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Essential Thrombocythemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Essential Thrombocythemia and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Essential Thrombocythemia by 14 companies/universities/institutes. The top development phase for Essential Thrombocythemia is phase ii with nine drugs in that stage. The Essential Thrombocythemia pipeline has 17 drugs in development by companies and one by universities/ institutes. Some of the companies in the Essential Thrombocythemia pipeline products market are: IO Biotech, Incyte and AbbVie.
The key targets in the Essential Thrombocythemia pipeline products market include Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2), Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98), and Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98).
The key mechanisms of action in the Essential Thrombocythemia pipeline product include Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Inhibitor with three drugs in Phase II. The Essential Thrombocythemia pipeline products include five routes of administration with the top ROA being Oral and five key molecule types in the Essential Thrombocythemia pipeline products market including Small Molecule, and Subunit Vaccine.
Essential Thrombocythemia overview
Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essential thrombocythemia, there is mainly an overproduction of platelet-forming cells (megakaryocytes) in the marrow. Symptoms of essential thrombocythemia include headache, dizziness, weakness or numbness on one side of the body, slurred speech, and transient ischemic attacks.
For a complete picture of Essential Thrombocythemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
